Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Introduction: Development of immune-related adverse events (irAEs) has been associated
with enhanced efficacy with the use of immune checkpoint inhibitors (ICIs). It remains …
with enhanced efficacy with the use of immune checkpoint inhibitors (ICIs). It remains …
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
Objectives Epigenomic alterations in cancer interact with the immune microenvironment to
dictate tumour evolution and therapeutic response. We aimed to study the regulation of the …
dictate tumour evolution and therapeutic response. We aimed to study the regulation of the …
Inferring cancer disease response from radiology reports using large language models with data augmentation and prompting
Objective To assess large language models on their ability to accurately infer cancer disease
response from free-text radiology reports. Materials and Methods We assembled 10 602 …
response from free-text radiology reports. Materials and Methods We assembled 10 602 …
Real‐world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: experience of a tertiary Asian Center
Introduction Immune checkpoint inhibitor (ICI) use in advanced hepatocellular carcinoma (HCC)
is increasing. Real‐world data on efficacy and safety, however, are lacking. Methods …
is increasing. Real‐world data on efficacy and safety, however, are lacking. Methods …
Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.
…, A Janitzky, M Wermke, L Nogova, DWM Tai… - 2018 - ascopubs.org
4513 Background: Activation of FGFR signaling is involved in a variety of malignancies including
advanced urothelial cancer (UC). Rogaratinib is an oral pan-FGFR kinase inhibitor. We …
advanced urothelial cancer (UC). Rogaratinib is an oral pan-FGFR kinase inhibitor. We …
[HTML][HTML] Gastric peritoneal carcinomatosis-a retrospective review
AIM To characterize patients with gastric peritoneal carcinomatosis (PC) and their typical
clinical and treatment course with palliative systemic chemotherapy as the current standard of …
clinical and treatment course with palliative systemic chemotherapy as the current standard of …
First-line systemic therapies for advanced hepatocellular carcinoma: a systematic review and patient-level network meta-analysis
Introduction: Sorafenib was historically the standard of care for advanced hepatocellular
carcinoma (aHCC) until it was superseded by the combination of atezolizumab and …
carcinoma (aHCC) until it was superseded by the combination of atezolizumab and …
Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies
Objectives Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality
and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA …
and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA …
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
Purpose Resistance to gemcitabine remains a key challenge in the treatment of pancreatic
ductal adenocarcinoma (PDAC), necessitating the constant search for effective strategies for …
ductal adenocarcinoma (PDAC), necessitating the constant search for effective strategies for …
Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.
…, A Janitzky, M Wermke, L Nogova, DWM Tai… - 2018 - ascopubs.org
494 Background: Activation of FGFR signaling is involved in a variety of malignancies including
advanced urothelial cancer (UC). Rogaratinib is an oral pan-FGFR kinase inhibitor. We …
advanced urothelial cancer (UC). Rogaratinib is an oral pan-FGFR kinase inhibitor. We …